Skip to content
Trial Agents

National Jewish Health

National Jewish Health is recorded as a service provider in 17 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.

17distinct trials
4recorded service labels
1trials with learnings

Data snapshot: 2026-10-09 · About the data

Clinical trial experience

Showing 17 of 17 trials · Latest update first

A phase 3, multicenter, randomized, double-blind, placebo- controlled, parallel-group study with an open-label period and long-term extension to assess the efficacy and safety of rilzabrutinib in participants with warm autoimmune hemolytic anemia (wAIHA)

Sponsor Sanofi-Aventis Recherche & Developpement

Start (EU)
Latest update
Estimated end

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ – CSU2)

Sponsor Celldex Therapeutics Inc.

Start (EU)
Latest update
Estimated end

A Phase 3, Randomized, Double-blind, Placebo-controlled, 3-Part Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-demand Treatment of Angioedema Attacks in Adults with Acquired Angioedema due to C1 Inhibitor Deficiency

Sponsor Pharvaris Netherlands B.V.

Start (EU)
Latest update
Estimated end

A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Sponsor Apellis Pharmaceuticals Inc.

Start (EU)
Latest update
Estimated end
Operational learnings available8 trial-level findings · Read insights
  • The study enrolled 124 participants at 122 sites across 18 countries; enrollment was highest in the United States (31), Brazil (19), and Italy (17).
  • Recruitment started on 30 May 2022, and the global end-of-trial date was 14 January 2025.
  • A protocol amendment changed planned enrollment from 90 to 80–100 participants.
  • An amendment removed eGFR from the primary efficacy endpoint and moved primary and key secondary efficacy assessments from Week 52 to Week 26.
  • An amendment increased the screening period from 8 to 10 weeks and total study participation duration to 70 weeks.
  • Eligibility and dosing amendments increased the minimum body weight to 30 kg and added weight-based dosing regimens for adolescents.
  • The minimum planned adolescent enrollment was increased from 8 to 10 participants.
  • Follow-up for participants who did not continue pegcetacoplan was shortened from 24 to 8 weeks.

These findings describe the trial, not the service provider’s performance or responsibility.

A Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-CSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects with Multiple Myeloma – The GENESIS Study

Sponsor Bioline Rx Ltd.

Start (EU)
Latest update
Estimated end

A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy

Sponsor Argenx

Start (EU)
Latest update
Estimated end

Questions about this trial experience

What services are recorded for National Jewish Health?

The 2026-10-09 snapshot links National Jewish Health to 17 distinct CTIS trials. Recorded services include Laboratory services, IgE receptor Antibody, Complement C3NeF analysis, Genetic testing. These are study-specific roles, not a complete or independently verified capability catalogue.

Which therapeutic areas and study phases are recorded for National Jewish Health?

The most frequently recorded therapeutic areas are Immunology, Allergy, Blood Disorders, Dermatology. Recorded phases include Phase 3, Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.

In which countries are trials linked to National Jewish Health conducted?

The linked trials record locations in 21 countries, including Germany, Spain, Italy, Netherlands, Poland. These are trial locations, not confirmed office locations or countries where National Jewish Health delivered services.

What can this page tell me about National Jewish Health's trial experience?

Browse 17 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.

About this data & company names

One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.

Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.

Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under National Jewish Health. Legacy brands remain separate unless explicitly matched in the name registry.

View recorded company names
  • National Jewish Health

Never miss a new clinical trial insight

We continuously analyze new and updated clinical trial data and publish practical, evidence-led reports for clinical leaders.

By entering your email, you agree to receive emails from Trial Agents. You can unsubscribe anytime.